Method
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
How a record gets onto this site, how it is classified, what the derived labels mean, and why every compound page here is currently withheld.
Where the records come from
Nothing on this site was written from a source read in full. The corpus holds, per compound, a selection of literature records with real identifiers, each carrying the subject headings and the publication type the indexer assigned to it. This site reads those fields and nothing else. It holds 186 records across 17 compounds; the queries behind them returned 48,938 records in total, so what is carried here is a selection and is named as one on every page that uses it.
How a record is assigned to an endpoint
An endpoint is a fixed list of MeSH subject headings. A record belongs to the endpoint when the indexer attached at least one heading from that list to it. The assignment is mechanical, it is reversible by hand against the lists below, and it carries no claim about what the record reported. A record can sit under several endpoints, and 10 of the records in scope sit under none.
Body weight and adiposity
Records whose assigned subject headings cover body mass, adiposity, energy intake or the agents indexed against them. 108 records in scope carry at least one of these headings, across all 17 compounds. The body weight and adiposity matrix.
Headings in the set: Obesity; Weight Loss; Body Weight; Body Mass Index; Anti-Obesity Agents; Overweight; Weight Gain; Body Composition; Waist Circumference; Adipose Tissue; Appetite Depressants; Appetite Regulation; Eating; Caloric Restriction; Body Size; Mice, Obese; Energy Metabolism; Leptin; Absorptiometry, Photon.
Glycaemic control
Records whose assigned subject headings cover blood glucose, glycated haemoglobin, insulin handling or the diabetes populations indexed alongside them. 117 records in scope carry at least one of these headings, across all 17 compounds. The glycaemic control matrix.
Headings in the set: Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1; Diabetes Mellitus; Diabetes Mellitus, Experimental; Blood Glucose; Glycated Hemoglobin; Glycemic Control; Hypoglycemic Agents; Hypoglycemia; Hyperglycemia; Insulin Resistance; Prediabetic State; Postprandial Period; Glucose; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Metformin.
Cardiovascular
Records whose assigned subject headings cover the heart, the vasculature or the cardiovascular events and measures indexed with them. 30 records in scope carry at least one of these headings, across 11 of the 17 compounds. The cardiovascular matrix.
Headings in the set: Cardiovascular Diseases; Heart Failure; Stroke Volume; Myocardial Infarction; Atherosclerosis; Blood Pressure; Diabetic Angiopathies; Heart Rate; Acute Coronary Syndrome; Atrial Fibrillation; Hypertension; Myocardial Contraction; Echocardiography; Natriuretic Peptide, Brain; Heart; Myocardium; Heart Atria; Heart Ventricles; Angina, Unstable; Tachycardia, Ventricular; Cardiotonic Agents; Pericardium; Endothelial Cells; Magnetic Resonance Imaging, Cine.
Renal
Records whose assigned subject headings cover kidney function, filtration rate, albuminuria or renal disease states. 10 records in scope carry at least one of these headings, across 7 of the 17 compounds. The renal matrix.
Headings in the set: Glomerular Filtration Rate; Diabetic Nephropathies; Albuminuria; Renal Insufficiency; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Kidney; Kidney Diseases; Creatinine; Kidney Function Tests.
Hepatic
Records whose assigned subject headings cover the liver, hepatic steatosis, fibrosis or the transaminases indexed with them. 9 records in scope carry at least one of these headings, across 9 of the 17 compounds. The hepatic matrix.
Headings in the set: Liver; Fatty Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Alanine Transaminase; Aspartate Aminotransferases; Liver Function Tests; Liver Diseases.
Neurological
Records whose assigned subject headings cover the central or peripheral nervous system, including the neurodegenerative populations this class has been indexed against. 18 records in scope carry at least one of these headings, across 8 of the 17 compounds. The neurological matrix.
Headings in the set: Parkinson Disease; Alzheimer Disease; Brain; Neurons; Cognition; Neuroprotective Agents; Neurodegenerative Diseases; Hippocampus; Hypothalamus; Antiparkinson Agents; tau Proteins; Neurofibrillary Tangles; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Vagus Nerve; Area Postrema; Paraventricular Hypothalamic Nucleus; Synapsins; Motor Activity; Motor Disorders; Neurologic Examination; Encephalitis; Migraine Disorders; Trigeminal Ganglion.
How a record class is read
Trial phase is read from the publication type the indexer assigned, never from the title and never from the abstract. A record with no trial publication type is not demoted to a lower phase: it is placed in a class that says it is not a registered trial record, which is a different statement.
| Record class | Assigned when the publication type contains |
|---|---|
| Phase 3 | Phase III |
| Phase 2 | Phase II |
| Phase 1 | Phase I |
| Trial, no phase assigned | Clinical Trial, Randomized Controlled Trial or Equivalence Trial, with no phase |
| Review or synthesis | Review, Systematic Review or Meta-Analysis, with no trial type |
| Not a registered trial record | none of the above |
What a derived tier is, and what it is not
The corpus carries a derived label per compound describing the shape of its indexed record set, together with the basis string it was computed from. It is labelled INFERRED in the data and it is only ever shown on this site beside that basis.
It counts record types. It is not an assessment of clinical efficacy, of safety, of how well any study was conducted, or of what the field concludes. It does not rank one compound above another, and no page here orders anything by it. A compound with fewer indexed records has been indexed less, which is a fact about this corpus and not a fact about the compound.
Unknown is a value
A field with no retrieved source reads Unknown. It is never left blank, never filled with a plausible figure and never filled from a similar compound. A zero in a matrix cell records that no indexed record for that compound carries one of the headings in that set. It is the absence of a retrieved report, never the absence of the thing itself.
Why the compound pages are withheld
The corpus marks a compound high impact when its name carries an application on the FDA register, when its indexed set contains an interventional human trial, or when it sits in a weight-management or metabolic class. All three apply across these two classes, so all 17 compounds in scope are high impact. None has a named qualified clinical reviewer recorded.
The build therefore refuses to publish any page that presents one of their record sets. Such a page is still built, still checked by every other gate, and still served at its URL. It carries a noindex directive and it is absent from the sitemap. Nothing is deleted, nothing is softened, and recording a named qualified reviewer publishes the page unchanged on the next build.
Compilation is not clinical validation. A citation check, a banned-phrase lint and a link audit establish that a page says what the corpus says. They establish nothing about whether what the corpus says is a fair reading of the field, and no automated check on this site claims otherwise. The review register lists the current state.